Atlas Trials

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial NCT00978432 · TERMINATED

Trial details

NCT number
NCT00978432
Sponsor
Anne Beaven, MD
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2012-02-01
Primary completion
2015-04-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.